de Las Heras Begoña, Saini Kamal S, Boyle Frances, Ades Felipe, de Azambuja Evandro, Bozovic-Spasojevic Ivana, Romano Marco, Capelan Marta, Prasad Rajeev, Pattu Pugazhenthi, Massard Christophe, Portera Chia, Saini Monika Lamba, Singh Brajendra Prasad, Venkitaraman Ramachandran, McNally Richard, Leone Manuela, Grande Enrique, Gupta Sudeep
Covance Inc., Princeton, NJ, USA.
Madrid Medical Doctors Association, Madrid, Spain.
Oncol Ther. 2020 Dec;8(2):171-182. doi: 10.1007/s40487-020-00124-2. Epub 2020 Aug 4.
The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy. In this article, we summarize emerging data related to patients with cancer and COVID-19. Among patients with COVID-19, a higher proportion have an underlying diagnosis of cancer than seen in the general population. Also, patients with malignancy are likely to be more vulnerable than the general population to contracting COVID-19. Mortality is significantly higher in patients with both cancer and COVID-19 compared with the overall COVID-19-positive population. The early months of the pandemic saw a decrease in cancer screening and diagnosis, as well as postponement of standard treatments, which could lead to excess deaths from cancer in the future.
2019年冠状病毒病（COVID-19）大流行对患有潜在恶性肿瘤的患者产生了重大影响。在本文中，我们总结了与癌症患者和COVID-19相关的新出现的数据。在COVID-19患者中，有癌症潜在诊断的比例高于普通人群。此外，恶性肿瘤患者可能比普通人群更容易感染COVID-19。与总体COVID-19阳性人群相比，同时患有癌症和COVID-19的患者死亡率显著更高。在大流行的最初几个月，癌症筛查和诊断减少，标准治疗推迟，这可能导致未来癌症超额死亡。
